IXICO Plc engages in the provision of technology-enabled specialty services to the global biopharmaceutical industry. The firm is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. The company advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.
最新の財務諸表(Form-10K)によると、Kinetic Development Group Ltdの総資産は$0で、純損失は$0です。
PHYOFの主要な財務比率は何ですか?
Kinetic Development Group Ltdの流動比率は0、純利益率は0、1株当たり売上高は$0です。
IXICO plcの収益はセグメントまたは地域別にどのように分けられていますか?
Kinetic Development Group Ltd の最大収益セグメントは Coal Mining で、最新の利益発表における収益は 4,895,618,910 です。地域別に見ると、China が Kinetic Development Group Ltd の主要市場であり、収益は 5,730,091,346 です。
IXICO plcは収益を上げていますか?
いいえ、最新の財務諸表によると、Kinetic Development Group Ltdの純損失は$0です。